| Autor: |
Garcia DC; Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA., Benjo AM; Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA., White CJ; Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA.; The University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans, LA., Cardoso RN; Department of Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, FL., Macedo FYB; Department of Cardiology, Baylor College of Medicine, Houston, TX., Schob AH; Department of Cardiology, Department of Internal Medicine, The Miami VA Hospital, Miami, FL., El-Hayek GE; Department of Internal Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY., Nadkarni GN; Department of Internal Medicine, Mount Sinai Hospital, New York, NY., Aziz EF; Department of Internal Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY., Patel RAG; Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA.; The University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans, LA. |
| Abstrakt: |
Background: Primary percutaneous coronary intervention (PCI) is the most frequently used treatment modality for patients presenting with ST elevation myocardial infarction (STEMI). Current professional society guidelines recommend culprit artery only PCI. Recent evidence suggests the potential benefit of multivessel PCI among patients with STEMI that is not complicated by cardiogenic shock. Methods: We systematically searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials for clinical studies of patients with STEMI, not complicated by cardiogenic shock, who underwent primary PCI between January 1966 and January 2018. We evaluated all-cause and cardiovascular mortality, reinfarction, and repeat revascularization among patients randomized to a multivessel PCI strategy compared to a culprit artery only PCI strategy. Results: Four randomized clinical trials with a total of 1,044 patients met the inclusion criteria. Five hundred and sixty-six patients underwent multivessel PCI, and 478 patients underwent culprit artery only PCI. Multivessel PCI reduced all the studied endpoints: total death, cardiac death, reinfarction, and repeat revascularization (all P values <0.05). Conclusion: To our knowledge, this is the largest metaanalysis of randomized controlled trials studying multivessel PCI vs culprit artery only PCI in STEMI patients without shock, among whom lesion severity was graded by angiography alone. We found that compared to culprit artery only PCI, the multivessel PCI strategy was beneficial in reducing all-cause and cardiovascular mortality, reinfarction, and the need for repeat revascularization. |
